StockWatch
·

SMS PHARMACEUTICALS LTD. Q2 FY27 Results

SMSPHARMAQ2 FY27 Results
Filing
Result:Very Good· Market: Up#Margin expansion#Record quarter#Broad based

Outlook: Optimistic · Guidance: Raised

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue316.0952.7%30.4%
Total Income317.4352.1%30.2%
Expenditure264.6145.8%26.1%
PBT52.8294.2%55.1%
Net Profit39.8590.6%57.4%
OPM21.40%1.61pp1.45pp
NPM12.55%2.53pp2.17pp
EPS4.2691.0%50.0%
View full financials

Pharma/API core metrics (revenue growth, PAT growth, OPM expansion) are all strongly up YoY with no one-off driving it — highest PAT in 6 quarters, ahead of management's own FY27 guidance.

SMS PHARMACEUTICALS · Q2 FY27 · THE VERDICT

Strong Execution on Backward Integration — But Can It Hold Through the Commodity Cycle?

SMS delivered a 30% revenue beat and raised FY27 guidance, backed by ibuprofen pricing and margin gains from backward integration. The risk: half the growth is driven by commodity cyclicality management expects to soften within 1–2 quarters, and a heavy capex program looms ahead.

10 Nov 2026 · 6 min read
Q2 Revenue

₹316.1 Cr

+30.4% YoY, +52.7% QoQ

Q2 PAT

₹39.9 Cr

+57.4% YoY, +90.6% QoQ

EBITDA Margin (Q2)

21.4%

expanded 145 bps QoQ from Q1

FY27 Guidance

Raised

now expect to exceed 15% target

The headline numbers are strong: Q2 revenue surged 30% YoY and PAT nearly doubled. Management backed this up by raising FY27 guidance, signalling confidence in the momentum. But the composition of that growth tells a different story. Half of the first-half revenue comes from ibuprofen—a cyclical commodity where prices are driving the majority of the gain. Management itself expects raw material cost pressure to continue for 1–2 quarters, which suggests the margin tailwind will soon face headwinds.

The ibuprofen story: pricing power, not volumes

H1 FY27 revenue landed at ₹523 Cr, up 19% YoY. Of that, roughly ₹150–160 Cr (50%) came from ibuprofen, a commodity API where SMS is ramping capacity from 90–95% utilization at 450–500 tonnes per month. Volume growth is strong but modest in absolute terms: management cited 10–15% YoY volume increase. The real story is pricing. Q2's 30% revenue jump was 30% price-driven, 10–15% volume-driven. That ratio is the risk. Commodities are cyclical; when capacity balances across the industry and global supply normalizes, pricing power evaporates.

It's a cyclical product, and it goes through many phases. There will be up phases, there will be down phases, there will be shortages, there'll be overcapacity.

Backward integration: real, but hedged

The margin expansion—145 bps QoQ, EBITDA margin to 21.4%—is driven by backward integration of ibuprofen raw materials. Prior to in-house production, ibuprofen EBITDA margin was below 10%; now it sits in the 'teens' (management declined to disclose exact %). This is structural and real. But management also signalled caution: they emphasised product stability and cost control as priorities, not margin expansion. And they expect raw material inflation to persist for 1–2 more quarters. In other words, the 145 bps gain is partly a catch-up from commodity deflation, not entirely a structural moat.

H1 FY27 Revenue Drivers
07.4714.9322.410Ibuprofen volumes20Ibuprofen pricing15HVA growth19Total organic %
Estimated contribution to H1 19% YoY growth. Ibuprofen pricing is cyclical; HVA is higher-margin and sustainable.
Claims on the call vs. what holds up

Revenue grew 30% YoY to ₹316 Cr

Exact match

Delivered ₹316.1 Cr, 30.4% YoY growth

PAT grew 57% to ₹39.6 Cr

Exact match

Delivered ₹39.9 Cr, 57.4% YoY growth

EBITDA grew 40% with 21% margin

Supported

Implies ₹48.6 Cr prior Q2; OPM 21.4% delivered

Ibuprofen utilization 90–95%, volumes ramping 450–500 T/month

Supported

10–15% volume growth YoY consistent with stated utilization

HVA now 49% of H1 revenue, up from 47% FY26

Supported

Implies ~₹256 Cr HVA in H1; portfolio mix improving

What changed on this call

  • FY27 revenue guidance raised: from 15% target to now expecting to exceed, backed by H1 19% growth

  • EBITDA margin target clarified: 22–24% for FY28 (vs. prior 20% FY26 aspiration), assumes raw material easing

  • Capex timeline and debt quantified: ₹280 Cr total, ₹160 Cr deployed H1, ₹120 Cr remaining before FY27-end. Peak debt ₹400 Cr.

  • Peptide R&D timeline extended: samples Q4 FY27 target, meaningful revenue 2–3 years out (not next year)

  • HVA revenue share grew from 47% FY26 to 49% H1; targeting <35% dependency on any single product

Bull-bear ledger
  • Backward integration margin gain: <10% → teens EBITDA on ibuprofen. Real and structural.

  • H1 growth momentum (19% YoY) and EBITDA margin (21%) support FY27 guidance raise.

  • HVA diversification: 49% of H1 revenue, growing, higher-margin than ibuprofen.

  • Ibuprofen 50% of H1 revenue; 30% of Q2 growth is pricing, not volume.

  • Raw material inflation expected 1–2 more quarters; margin tailwind will face headwinds.

  • Capex execution risk: ₹120 Cr remaining; peak debt ₹400 Cr creates leverage constraint.

  • Peptides early-stage; no customer wins yet; 2–3 year revenue timeline remains speculative.

  • Management guidance credible on execution and ibuprofen demand; held line on cyclicality risk.

Ranked risks: severity and why they matter to a holder

Ibuprofen commodity cyclicality

High

50% of H1 revenue is ibuprofen. Pricing drives 30% of Q2 growth; management expects commodity pressure 1–2 quarters. When supply normalizes, pricing power evaporates and margins compress. No structural growth story without volume ramp.

Capex execution and debt leverage

High

₹120 Cr capex remaining in 4–6 month window before FY27-end. Peak debt ₹400 Cr by FY27-end constrains balance sheet flexibility. Delays could impact revenue ramp and margin trajectory. Interest burden already material (₹15+ Cr incremental cited).

Peptide commercialization timeline

Medium

R&D started a few months ago. Pilot samples Q4 FY27 target; meaningful revenue 2–3 years out. No customer LOIs or pilot contracts signed as of call. Key long-term growth driver but highly uncertain execution.

Raw material price inflation

Medium

Ongoing pressure expected 1–2 more quarters. Gross margin headwind even with backward integration; cost control ongoing (batch sizes ~10 tons now). If inflation persists longer, margin expansion stalls.

High-value API concentration

Medium

HVA 49% of H1, up from 47% FY26. No customer concentration details disclosed. Regulatory or pricing pressure on any large HVA customer (ARV, anti-ED, antibiotic) could impact earnings. Diversification ongoing (6–8 new launches FY28) but still speculative.

How the street is positioned

The stock is priced at ₹513.2 as of this report, near its all-time high of ₹535 (only 4% below ATH). It has rallied 90% from its 52-week low of ₹270. The trend is BULLISH, but RSI at 63 (NEUTRAL) suggests limited near-term upside without a fresh catalyst. The market has repriced the stock for the guidance raise and backward integration margin improvement. Foreign institutional inflows are picking up: FII stake rose to 0.65% in Q1 FY27 from 0.31% in Q4 FY26 (+34 bps inflow). Domestic institutions trimmed slightly (DII 2.83% from 3.02%); promoters unchanged at 68.07%. Block deal activity shows routine trading with no insider selling near highs. The tape confirms the bulls are in control, but valuation and positioning leave little room for surprise. The next move likely hinges on whether raw material costs stabilize faster than expected or capex execution hiccups.

What to watch next
  • 1 · Raw material price trend (next 1–2 quarters)

    Management's 1–2 quarter guidance is the key risk. If global prices normalize sooner, margin upside to FY28 target (22–24%) is intact. If inflation persists, the 145 bps Q1–Q2 gain will reverse.

  • 2 · Capex completion and debt servicing (Q1–Q3 FY27)

    ₹120 Cr remaining to deploy by FY27-end. Completion of 9,600 MT ibuprofen capacity would unlock incremental ~₹100 Cr+ revenue at scale. Debt peak ₹400 Cr is manageable if EBITDA grows 20%+ but becomes a constraint if growth stalls.

  • 3 · Peptide samples and customer engagement (Q4 FY27)

    Q4 FY27 target for pilot samples. Any CRO/CDMO customer LOI or pilot contract would materially de-risk the 2–3 year revenue pathway and justify the long-term growth thesis.

  • 4 · HVA new molecule launches (FY28)

    6–8 launches on track. These are critical to reduce ibuprofen dependency to <35%. Evidence of regulatory approval or customer acceptance would validate the portfolio diversification thesis.

SMS delivered solid execution on backward integration and raised FY27 guidance credibly on H1 momentum. But the growth is driven by ibuprofen commodity pricing and margin expansion that management itself expects to soften in 1–2 quarters. The capex program (₹120 Cr remaining, ₹400 Cr peak debt) and peptide timeline (2–3 years to revenue) add execution risk. The stock is already near all-time highs with FII buying in. The number to track from here is organic volume growth and raw material cost stabilization, not headline profit. Execution on capex and capex-driven capacity ramp is the near-term catalyst; peptides and new molecules are the long-term optionality. Until raw material pressure eases and organic growth becomes the driver, the upside is hedged.

Informational and educational content only. Not investment advice.